DongKook Pharmaceutical Co (086450) Fair Value & Analysis
Healthcare · KR · Market cap 870B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 20 days ago
Share price +3.2% over the past month.
A solid business, screening 67% undervalued on our models.
What matters now
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (16,863 KRW to 40,898 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 12,623 KRW – 29,900 KRW · fair‑value band 16,863 KRW – 40,898 KRW · the 19,300 KRW price screens below the 32,142 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
DongKook Pharmaceutical Co (086450) currently trades at 19,300 KRW, while our model-based Fair Value estimate is 32,142 KRW, implying the stock looks roughly 66.5% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, DongKook Pharmaceutical Co generated revenue of 646B KRW at a net margin of 9.1%. Revenue grew 10.1% year over year. Net debt stands at 11.6B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 16,863 KRW (bear case) to 40,898 KRW (bull case); at 19,300 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 67%, 086450 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (31,106 KRW) versus Asset-Based (10,018 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug …
Full company description
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durakinase, and Lorelin Depot injections; produces various natural product materials, such as black cohosh extract and magnolia extract comprises ETIZM and TECA; and natural herb medicines. In addition, it provides general and prescription-based drugs; medical devices; ETC and cosmetic products; and quasi drugs that include lipossol hydrocare bandage. DongKook Pharmaceutical Co., Ltd. also exports its products to approximately 40 countries, including Japan, Europe, Central and South America, and India. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DongKook Pharmaceutical Co reported revenue of 927B KRW in FY2025 versus 594B KRW in FY2021, a compound +11.8%/yr. Reported net income was 66.0B KRW in FY2025, compounding +7.0%/yr from FY2021.
Watch 086450: get an alert when its fair value changes →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceuticals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,653 | ₹1,471 | -45% |
| Caregen Co 214370 | 62,700 KRW | 7,277 KRW | -88% |
| ST Pharm Co 237690 | 123,600 KRW | 50,110 KRW | -59% |
| Oscotec Inc 039200 | 31,050 KRW | 25,062 KRW | -19% |
| Kolon Life Science Inc 102940 | 30,100 KRW | 37,195 KRW | +24% |
| Huons Global Co 084110 | 23,800 KRW | 58,482 KRW | +146% |
| BINEX Co 053030 | 6,350 KRW | 1,844 KRW | -71% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 16,810 KRW | 4,741 KRW | -72% |
| EURO EURO | 1.09 PHP | 0.8700 PHP | -20% |
| Kyung Dong Pharmaceutical Co 011040 | 4,935 KRW | 6,165 KRW | +25% |
Compare DongKook Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DongKook Pharmaceutical Co (086450) overvalued or undervalued?
What is the fair value of 086450?
What is the quality score of 086450?
What is the revenue of DongKook Pharmaceutical Co (086450)?
What is the net profit margin of 086450?
Does DongKook Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track DongKook Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.